ABSTRACT
A new evaluation of previously published data suggested to us that the accumulation of mutations might slow, rather than increase, as individuals age. To explain this unexpected finding, we hypothesized that normal stem cell division rates might decrease as we age. To test this hypothesis, we evaluated cell division rates in the epithelium of human colonic, duodenal, esophageal, and posterior ethmoid sinonasal tissues. In all 4 tissues, there was a significant decrease in cell division rates with age. In contrast, cell division rates did not decrease in the colon of aged mice, and only small decreases were observed in their small intestine or esophagus. These results have important implications for understanding the relationship between normal stem cells, aging, and cancer. Moreover, they provide a plausible explanation for the enigmatic age-dependent deceleration in cancer incidence in very old humans but not in mice.
Subject(s)
Aging , Cell Division , Deceleration , Mutation , Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , Animals , Colon/cytology , Colon/metabolism , Duodenum/cytology , Duodenum/metabolism , Esophagus/cytology , Esophagus/metabolism , Humans , Incidence , Ki-67 Antigen/metabolism , Male , Mice , Mice, Inbred C57BL , Neoplasms/pathology , Paranasal Sinuses/cytology , Paranasal Sinuses/metabolism , Young AdultABSTRACT
Intraductal papillary mucinous neoplasms (IPMNs) are precursors to pancreatic cancer; however, little is known about genetic heterogeneity in these lesions. The objective of this study was to characterize genetic heterogeneity in IPMNs at the single-cell level. We isolated single cells from fresh tissue from ten IPMNs, followed by whole genome amplification and targeted next-generation sequencing of pancreatic driver genes. We then determined single-cell genotypes using a novel multi-sample mutation calling algorithm. Our analyses revealed that different mutations in the same driver gene frequently occur in the same IPMN. Two IPMNs had multiple mutations in the initiating driver gene KRAS that occurred in unique tumor clones, suggesting the possibility of polyclonal origin or an unidentified initiating event preceding this critical mutation. Multiple mutations in later-occurring driver genes were also common and were frequently localized to unique tumor clones, raising the possibility of convergent evolution of these genetic events in pancreatic tumorigenesis. Single-cell sequencing of IPMNs demonstrated genetic heterogeneity with respect to early and late occurring driver gene mutations, suggesting a more complex pattern of tumor evolution than previously appreciated in these lesions. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Subject(s)
Genetic Heterogeneity , Pancreatic Intraductal Neoplasms/genetics , Aged , Aged, 80 and over , DNA Mutational Analysis/methods , Female , Genes, Neoplasm/genetics , Genetic Predisposition to Disease , High-Throughput Nucleotide Sequencing , Humans , Male , Middle Aged , Mutation , Pancreatic Intraductal Neoplasms/pathology , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathology , Proto-Oncogene Proteins p21(ras)/geneticsABSTRACT
OBJECTIVES: To describe the survival outcome of patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (BR/LA-PDAC) who have a pathologic complete response (pCR) following neoadjuvant chemoradiation. BACKGROUND: Patients with BR/LA-PDAC are often treated with neoadjuvant chemoradiation in an attempt to downstage the tumor. Uncommonly, a pCR may result. METHODS: A retrospective review of a prospectively maintained database was performed at a single institution. pCR was defined as no viable tumor identified in the pancreas or lymph nodes by pathology. A near complete response (nCR) was defined as a primary tumor less than 1âcm, without nodal metastasis. Overall survival (OS) and disease-free survival (DFS) were reported. RESULTS: One hundred eighty-six patients with BR/LA-PDAC underwent neoadjuvant chemoradiation and subsequent pancreatectomy. Nineteen patients (10%) had a pCR, 29 (16%) had an nCR, and the remaining 138 (74%) had a limited response. Median DFS was 26 months in patients with pCR, which was superior to nCR (12 months, P = 0.019) and limited response (12 months, P < 0.001). The median OS of nCR (27 months, P = 0.003) or limited response (26 months, P = 0.001) was less than that of pCR (more than 60 months). In multivariable analyses pCR was an independent prognostic factor for DFS (HR = 0.45; 0.22-0.93, P = 0.030) and OS (HR=0.41; 0.17-0.97, P = 0.044). Neoadjuvant FOLFIRINOX (HR=0.47; 0.26-0.87, P = 0.015) and negative lymph node status (HR=0.57; 0.36-0.90, P = 0.018) were also associated with improved survival. CONCLUSIONS: Patients with BR/LA-PDAC who had a pCR after neoadjuvant chemoradiation had a significantly prolonged survival compared with those who had nCR or a limited response.
Subject(s)
Carcinoma, Pancreatic Ductal/therapy , Chemoradiotherapy, Adjuvant , Neoadjuvant Therapy , Pancreatic Neoplasms/therapy , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Pancreatic Ductal/mortality , Carcinoma, Pancreatic Ductal/pathology , Female , Fluorouracil/therapeutic use , Follow-Up Studies , Humans , Irinotecan/therapeutic use , Leucovorin/therapeutic use , Lymphatic Metastasis , Male , Middle Aged , Oxaliplatin/therapeutic use , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Prognosis , Radiosurgery , Retrospective Studies , Survival AnalysisABSTRACT
OBJECTIVE: We assessed circulating tumor cells (CTCs) with epithelial and mesenchymal phenotypes as a potential prognostic biomarker for patients with pancreatic adenocarcinoma (PDAC). BACKGROUND: PDAC is the fourth leading cause of cancer death in the United States. There is an urgent need to develop biomarkers that predict patient prognosis and allow for better treatment stratification. METHODS: Peripheral and portal blood samples were obtained from 50 patients with PDAC before surgical resection and filtered using the Isolation by Size of Epithelial Tumor cells method. CTCs were identified by immunofluorescence using commercially available antibodies to cytokeratin, vimentin, and CD45. RESULTS: Thirty-nine patients (78%) had epithelial CTCs that expressed cytokeratin but not CD45. Twenty-six (67%) of the 39 patients had CTCs which also expressed vimentin, a mesenchymal marker. No patients had cytokeratin-negative and vimentin-positive CTCs. The presence of cytokeratin-positive CTCs (P < 0.01), but not mesenchymal-like CTCs (P = 0.39), was associated with poorer survival. The presence of cytokeratin-positive CTCs remained a significant independent predictor of survival by multivariable analysis after accounting for other prognostic factors (P < 0.01). The detection of CTCs expressing both vimentin and cytokeratin was predictive of recurrence (P = 0.01). Among patients with cancer recurrence, those with vimentin-positive and cytokeratin-expressing CTCs had decreased median time to recurrence compared with patients without CTCs (P = 0.02). CONCLUSIONS: CTCs are an exciting potential strategy for understanding the biology of metastases, and provide prognostic utility for PDAC patients. CTCs exist as heterogeneous populations, and assessment should include phenotypic identification tailored to characterize cells based on epithelial and mesenchymal markers.
Subject(s)
Adenocarcinoma/pathology , Adenocarcinoma/surgery , Neoplastic Cells, Circulating/metabolism , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , Female , Fluorescent Antibody Technique , Humans , Immunohistochemistry , Keratins/blood , Leukocyte Common Antigens/blood , Male , Middle Aged , Neoplasm Recurrence, Local , Phenotype , Prognosis , Survival Rate , Vimentin/bloodABSTRACT
Many patients with pancreatic cancer have metastases to distant organs at the time of initial presentation. Recent studies examining the evolution of pancreatic cancer at the genetic level have shown that clonal complexity of metastatic pancreatic cancer is already initiated within primary tumors, and organ-specific metastases are derived from different subclones. However, we do not yet understand to what extent the evolution of pancreatic cancer contributes to proteomic and signaling alterations. We hypothesized that genetic heterogeneity of metastatic pancreatic cancer results in heterogeneity at the proteome level. To address this, we employed a model system in which cells isolated from three sites of metastasis (liver, lung, and peritoneum) from a single patient were compared. We used a SILAC-based accurate quantitative proteomic strategy combined with high-resolution mass spectrometry to analyze the total proteome and tyrosine phosphoproteome of each of the distal metastases. Our data revealed distinct patterns of both overall proteome expression and tyrosine kinase activities across the three different metastatic lesions. This heterogeneity was significant because it led to differential sensitivity of the neoplastic cells to small molecule inhibitors targeting various kinases and other pathways. For example, R428, a tyrosine kinase inhibitor that targets Axl receptor tyrosine kinase, was able to inhibit cells derived from lung and liver metastases much more effectively than cells from the peritoneal metastasis. Finally, we confirmed that administration of R428 in mice bearing xenografts of cells derived from the three different metastatic sites significantly diminished tumors formed from liver- and lung-metastasis-derived cell lines as compared with tumors derived from the peritoneal metastasis cell line. Overall, our data provide proof-of-principle support that personalized therapy of multiple organ metastases in a single patient should involve the administration of a combination of agents, with each agent targeted to the features of different subclones.
Subject(s)
Benzocycloheptenes/therapeutic use , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/pathology , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins/antagonists & inhibitors , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Triazoles/therapeutic use , Animals , Antineoplastic Agents/therapeutic use , Cells, Cultured , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/genetics , Liver Neoplasms/secondary , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Lung Neoplasms/secondary , Mass Spectrometry , Mice , Molecular Targeted Therapy , Pancreatic Neoplasms/genetics , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/genetics , Peritoneal Neoplasms/secondary , Precision Medicine , Proteomics , Signal Transduction/genetics , Xenograft Model Antitumor Assays , Axl Receptor Tyrosine KinaseABSTRACT
Many sentinel lymph node biopsies (SLNBs) are evaluated intraoperatively by frozen section, which may impact the need for further axillary dissection (AD). However, the need for AD in patients with small metastases has been recently called into question, meaning that frozen SLNB may be unnecessary. Furthermore, frozen section can compromise tissue for further study. At our institution, we grossly evaluate all SLNB and freeze half of the node. Here, we evaluate the frozen SLNB discrepancy rate using this method, focusing on cause of discrepancy and need for further surgery. We reviewed surgical pathology records for all breast cancer resections with frozen section of SLNB examined from 2003 to 2012. For cases with a frozen section discrepancy, we compiled clinicopathologic data. In total, 1,940 cases involved frozen section evaluation of SLNB. In 95 cases (4.9% of total cases, 23.8% of positive node cases), the SLNB was called negative on frozen but positive on final examination (false negatives). The majority of missed metastases are isolated tumor cells or micrometastases. A trend was observed toward fewer patients receiving completion AD after a discrepant frozen SLNB in the later years of the study. The protocol of freezing half of a SLNB is a reasonable method, with results similar to or better than other studies. The main adverse outcome is the need for separate AD; however, additional positive nodes are uncommon. The trend of fewer patients getting additional AD after a discrepant frozen SLNB suggests that clinicians may be using this information differently recently.
Subject(s)
Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/secondary , Carcinoma, Lobular/secondary , Frozen Sections , Sentinel Lymph Node Biopsy , Adult , Aged , Aged, 80 and over , Axilla , Breast Neoplasms/surgery , Carcinoma, Ductal, Breast/surgery , Carcinoma, Lobular/surgery , Female , Follow-Up Studies , Humans , Lymph Node Excision , Lymphatic Metastasis , Middle Aged , Neoplasm Micrometastasis , Neoplasm Staging , Prognosis , Retrospective Studies , Young AdultABSTRACT
Pathological glomerular hyposialylation has been implicated in certain unexplained glomerulopathies, including minimal change nephrosis, membranous glomerulonephritis, and IgA nephropathy. We studied our previously established mouse model carrying a homozygous mutation in the key enzyme of sialic acid biosynthesis, N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. Mutant mice died before postnatal day 3 (P3) from severe glomerulopathy with podocyte effacement and segmental glomerular basement membrane splitting due to hyposialylation. Administration of the sialic acid precursor N-acetylmannosamine (ManNAc) led to improved sialylation and survival of mutant pups beyond P3. We determined the onset of the glomerulopathy in the embryonic stage. A lectin panel, distinguishing normally sialylated from hyposialylated glycans, used WGA, SNA, PNA, Jacalin, HPA, and VVA, indicating glomerular hyposialylation of predominantly O-linked glycoproteins in mutant mice. The glomerular glycoproteins nephrin and podocalyxin were hyposialylated in this unique murine model. ManNAc treatment appeared to ameliorate the hyposialylation status of mutant mice, indicated by a lectin histochemistry pattern similar to that of wild-type mice, with improved sialylation of both nephrin and podocalyxin, as well as reduced albuminuria compared with untreated mutant mice. These findings suggest application of our lectin panel for categorizing human kidney specimens based on glomerular sialylation status. Moreover, the partial restoration of glomerular architecture in ManNAc-treated mice highlights ManNAc as a potential treatment for humans affected with disorders of glomerular hyposialylation.
Subject(s)
Disease Models, Animal , Kidney Diseases/genetics , Animals , Biomarkers/metabolism , Carbohydrate Epimerases/genetics , Carrier Proteins/genetics , Dietary Supplements , Drug Evaluation, Preclinical/methods , Hexosamines/therapeutic use , Humans , Kidney Diseases/drug therapy , Kidney Diseases/metabolism , Kidney Diseases/pathology , Kidney Glomerulus/embryology , Kidney Glomerulus/metabolism , Kidney Glomerulus/ultrastructure , Membrane Proteins/metabolism , Mice , Mice, Mutant Strains , Microscopy, Electron , Mutation , N-Acetylneuraminic Acid/physiology , Podocytes/metabolism , Podocytes/ultrastructure , Real-Time Polymerase Chain Reaction/methods , Sialoglycoproteins/metabolismABSTRACT
BACKGROUND: Hereditary inclusion body myopathy (HIBM) is an autosomal recessive adult onset myopathy. It is characterized by mutations of the GNE (UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase) gene. Afflicted patients have no therapeutic options. In preclinical testing, we have previously demonstrated the ability to correct GNE gene function and the safety of delivery of wild type GNE gene using a liposomal delivery vehicle. METHODS: A single patient (subject #001) with severe HIBM treated by compassionate investigational new drug received four doses of GNE gene Lipoplex via intramuscular injection. GNE transgene expression, downstream induction of sialic acid, safety and muscle function were evaluated. RESULTS: Significant durable improvement in locoregional skeletal muscle function was observed in the injected left extensor carpi radialis longus of #001 in correlation with GNE transgene upregulation and local induction of sialic acid. Other than transient low grade fever and pain at the injection site, no significant toxicity was observed. CONCLUSIONS: Proof of principle for manufacturing of 'clinical grade' GNE gene Lipoplex, clinical safety and activity are demonstrated with GNE gene Lipoplex. Further assessment will involve intravenous administration and subsequent phase I trial involving additional but less severely afflicted HIBM patients.
Subject(s)
Genetic Therapy , Liposomes/metabolism , Multienzyme Complexes/genetics , Multienzyme Complexes/therapeutic use , Myositis, Inclusion Body/genetics , Myositis, Inclusion Body/therapy , Adolescent , Adult , Biopsy , Female , Genetic Therapy/adverse effects , Humans , Injections, Intramuscular , Muscle Strength , Muscle, Skeletal/pathology , Muscle, Skeletal/physiopathology , Myositis, Inclusion Body/physiopathology , N-Acetylneuraminic Acid/metabolism , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Young AdultABSTRACT
PURPOSE: We hypothesized that functional TGFbeta1 SNPs increase TGFbeta/BMP signaling imbalance in BMPR2 mutation heterozygotes to accelerate the age at diagnosis, increase the penetrance and SMAD2 expression in familial pulmonary arterial hypertension. METHODS: Single nucleotide polymorphism genotypes of BMPR2 mutation heterozygotes, age at diagnosis, and penetrance of familial pulmonary arterial hypertension were compared and SMAD2 expression was studied in lung sections. RESULTS: BMPR2 mutation heterozygotes with least active -509 or codon 10 TGFbeta1 SNPs had later mean age at diagnosis of familial pulmonary arterial hypertension (39.5 and 43.2 years) than those with more active genotypes (31.6 and 33.1 years, P = 0.03 and 0.02, respectively). Kaplan-Meier analysis also showed that those with the less active single nucleotide polymorphisms had later age at diagnosis. BMPR2 mutation heterozygotes with nonsense-mediated decay resistant BMPR2 mutations and the least, intermediate and most active -509 TGFbeta1 SNP genotypes had penetrances of 33, 72, and 80%, respectively (P = 0.003), whereas those with 0-1, 2, or 3-4 active single nucleotide polymorphism alleles had penetrances of 33, 72, and 75% (P = 0.005). The relative expression of TGFbeta1 dependent SMAD2 was increased in lung sections of those with familial pulmonary arterial hypertension compared with controls. CONCLUSIONS: The TGFbeta1 SNPs studied modulate age at diagnosis and penetrance of familial pulmonary arterial hypertension in BMPR2 mutation heterozygotes, likely by affecting TGFbeta/BMP signaling imbalance. This modulation is an example of Synergistic Heterozygosity.
Subject(s)
Bone Morphogenetic Protein Receptors, Type II/genetics , Heterozygote , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/genetics , Penetrance , Transforming Growth Factor beta1/genetics , Adult , Age Factors , Female , Humans , Hypertension, Pulmonary/metabolism , Male , Mutation , Pedigree , Polymorphism, Single Nucleotide , Smad2 Protein/metabolism , Transforming Growth Factor beta1/metabolismABSTRACT
Breast adenoid cystic carcinoma (ACC) is a primary breast carcinoma that, like salivary gland ACC, displays the t(6;9) translocation resulting in the MYB-NFIB gene fusion and immunopositivity for MYB by immunohistochemistry (IHC). However, it is not well established whether MYB immunoreactivity or rearrangement can be used to support a diagnosis of ACC in a malignant basaloid or benign cribriform breast lesion. Whole sections of primary breast ACC (n=11), collagenous spherulosis (CS; n=7), and microglandular adenosis (MGA; n=5) and tissue microarrays containing 16 basal-like, triple-negative breast carcinomas (TNBC) were labeled for MYB by IHC and underwent MYB fluorescence in situ hybridization using a break-apart probe. Strong, diffuse nuclear MYB labeling was seen in 100% ACC compared with no cases of basal-like TNBC, CS, or MGA (P=0.0001). Any degree of nuclear MYB labeling was seen in 100% ACC compared with 54% of all other cases (P=0.007), with any labeling seen in 71% CS, 63% basal-like TNBC, and 0% MGA. MYB rearrangement was detected in 89% (8/9) of evaluable ACC compared with 4% (1/26) of all other evaluable cases (P=0.0001), with a rearrangement detected in 1 (7%; n=1/15) evaluable basal-like TNBC. Strong, diffuse nuclear labeling for MYB is more sensitive than MYB fluorescence in situ hybridization for breast ACC and can be used to support a diagnosis of ACC in a cribriform or basaloid lesion in the breast. However, weak and focal labeling should be interpreted with caution as it can be seen in other benign cribriform and malignant basaloid lesions.
Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/diagnosis , Carcinoma, Adenoid Cystic/diagnosis , Proto-Oncogene Proteins c-myb/metabolism , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/genetics , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Carcinoma, Adenoid Cystic/genetics , Carcinoma, Adenoid Cystic/metabolism , Carcinoma, Adenoid Cystic/pathology , Female , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Middle Aged , Proto-Oncogene Proteins c-myb/genetics , Retrospective Studies , Sensitivity and Specificity , Tissue Array Analysis , Translocation, GeneticABSTRACT
We describe an 85-yr-old male of Ashkenazi Jewish descent with biopsy-proven locally advanced pancreatic ductal adenocarcinoma (PDA). The patient underwent a modified course of gemcitabine and stereotactic body radiation therapy and survived for 42 mo with a stable pancreatic head mass and no evidence of metastatic disease before death due to complications from a stroke. Whole-exome sequencing of his tumor revealed a simple genome landscape with no evidence of mutations, copy-number changes, or structural alterations in genes most commonly associated with PDA (i.e., KRAS, CDKN2A, TP53, or SMAD4). An analysis of his germline DNA revealed no pathogenic variants of significance. Whole-exome and whole-genome sequencing identified a somatic mutation of RNF213 and an inversion/deletion of CTNNA2 as the genetic basis of his PDA. Although PDA is classically characterized by a predictable set of mutations, these data suggest that alternate genetic paths to PDA may exist, which can be associated with a more indolent clinical course.
Subject(s)
Adenosine Triphosphatases/genetics , Carcinoma, Pancreatic Ductal/genetics , Ubiquitin-Protein Ligases/genetics , alpha Catenin/genetics , Adenocarcinoma/genetics , Adenosine Triphosphatases/metabolism , Aged, 80 and over , Carcinoma, Pancreatic Ductal/drug therapy , Deoxycytidine/analogs & derivatives , Deoxycytidine/therapeutic use , Exome , Genomics , Humans , INDEL Mutation/genetics , Mutation , Pancreas/metabolism , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/genetics , Ubiquitin-Protein Ligases/metabolism , Exome Sequencing , alpha Catenin/metabolism , Gemcitabine , Pancreatic NeoplasmsABSTRACT
Purpose: TP53 and the TGFß pathway are major mediators of pancreatic cancer metastasis. The mechanisms by which they cause hematogenous metastasis have not been fully explored.Experimental Design:KPC (LSL-KRASG12D/+;LSL-Trp53R172H/+; Ptf1aCre/+) mice were generated, and the frequency and morphology of organ-specific hematogenous metastases compared with that seen in KPTC and KTC littermates (Tgfbr2+/-). Key findings were validated in primary cells from each genotype and samples of human pancreatic cancer liver metastases.Results: The frequency of hematogenous metastasis in KPTC mice was significantly lower than for KPC mice (41% vs. 68%, P < 0.05), largely due to a reduction in liver metastases. No differences were found between KPC and KPTC lung metastases, whereas liver metastases in KPTC mice showed a profound extravasation deficiency characterized by sinusoidal growth and lack of desmoplastic stroma. Analogous findings were confirmed in liver samples from patients indicating their clinical relevance. Portal vein colonization as a direct mode of access to the liver was observed in both mice and humans. Secretome analyses of KPC cells revealed an abundance of secreted prometastatic mediators including Col6A1 and Lcn2 that promoted early steps of metastatic colonization. These mediators were overexpressed in primary tumors but not metastases, suggesting that the ability to colonize is, in part, developed within the primary site, a phenomenon we refer to as the "Cinderella effect."Conclusions: These findings establish a novel paradigm for understanding pancreatic cancer metastasis and the observed clinical latencies of liver versus lung metastases specifically. Clin Cancer Res; 23(6); 1607-20. ©2016 AACR.
Subject(s)
Liver Neoplasms/genetics , Neoplasms, Experimental/genetics , Pancreatic Neoplasms/genetics , Tumor Suppressor Protein p53/genetics , Animals , Disease Models, Animal , Humans , Liver Neoplasms/pathology , Liver Neoplasms/secondary , Mice , Mice, Transgenic , Neoplasm Metastasis/genetics , Neoplasm Metastasis/pathology , Neoplasms, Experimental/pathology , Pancreas/pathology , Pancreatic Neoplasms/pathology , Protein Serine-Threonine Kinases/genetics , Proto-Oncogene Proteins p21(ras)/genetics , Receptor, Transforming Growth Factor-beta Type II , Receptors, Transforming Growth Factor beta/genetics , Signal Transduction/genetics , Transcription Factors/genetics , Transforming Growth Factor beta/geneticsABSTRACT
PURPOSE: We report a very unique case of an esophageal metastasis from a pancreatic ductal adenocarcinoma (PDAC) primary. METHODS: After obtaining consent from the patient, all relevant records of the case were obtained and retrospectively reviewed. RESULTS: At presentation, the patient was diagnosed with synchronous pancreatic and esophageal cancer. He received six months of neoadjuvant therapy including FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) and stereotactic body radiation therapy (SBRT) to the pancreatic tumor followed by a combined pancreaticoduodenectomy and Ivor Lewis esophagectomy. Review of the final esophageal specimen revealed normal overlying squamous mucosa with an underlying focus of metastatic PDAC. The patient remains alive with no evidence of disease 17 months from surgery and 25 months from diagnosis. CONCLUSIONS: Differentiating an esophageal metastasis from a PDAC primary versus a synchronous esophageal carcinoma is very difficult despite state-of-the-art diagnostic techniques performed at a high-volume tertiary cancer center. Extensive evaluation and continued follow-up of PDAC patients presenting with a synchronous esophageal lesion in a multidisciplinary setting may help ensure efficient and accurate management. In our case, neoadjuvant FOLFIRINOX and SBRT to the primary PDAC tumor followed by surgery has been an effective approach for this patient.
ABSTRACT
Background: Synchronous cystic lesions of the pancreas with different pathophysiology in the same patient are a rare occurrence.. Case Presentation: We report the incidental finding of a multicystic lesion within the pancreatic head in a morbidly obese woman during workup for bariatric surgery. The lesion contained an intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia within an acinar cell cystadenoma (ACA). ACAs are rare tumors first described in 2002. Conclusion: To date, there have been no published reports of synchronous IPMN within an ACA. This case report intends to increase provider awareness of these lesions as well as highlight the importance of surveillance and careful histological examination of heterogeneous cystic lesions of the pancreas.
ABSTRACT
Pancreatic neuroendocrine tumors (PanNETs) are the second most common pancreatic malignancy and cause significant morbidity and mortality. Neuroendocrine microadenomas have been proposed as a potential precursor lesion for sporadic PanNETs. In this study, we applied telomere-specific fluorescent in situ hybridization (FISH) to a series of well-characterized sporadic neuroendocrine microadenomas and investigated the prevalence of alterations in known PanNET driver genes (MEN1 and ATRX/DAXX) in these same tumors using immunohistochemistry for the encoded proteins. We identified aberrant Menin expression in 14 of 19 (74%) microadenomas, suggesting that alterations in Menin, at least a subset of which was likely due to somatic mutation, are early events in pancreatic neuroendocrine tumorigenesis. In contrast, none of the microadenomas met criteria for the alternative lengthening of telomeres phenotype (ALT) based on telomere FISH, a phenotype that is strongly correlated to ATRX or DAXX mutations. Two of 13 microadenomas (15%) were noted to have very rare abnormal bright telomere foci on FISH, suggestive of early ALT, but these lesions did not show loss of ATRX or DAXX protein expression by immunohistochemistry. Overall, these data suggest that loss of Menin is an early event in pancreatic neuroendocrine tumorigenesis and that ATRX/DAXX loss and ALT are relatively late events.
Subject(s)
Adenoma/genetics , Biomarkers, Tumor/genetics , Neuroendocrine Tumors/genetics , Pancreatic Neoplasms/genetics , Proto-Oncogene Proteins/genetics , Adaptor Proteins, Signal Transducing/analysis , Adenoma/chemistry , Adenoma/pathology , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Co-Repressor Proteins , DNA Helicases/analysis , Disease Progression , Female , Genetic Predisposition to Disease , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Male , Middle Aged , Molecular Chaperones , Mutation , Neuroendocrine Tumors/chemistry , Neuroendocrine Tumors/pathology , Nuclear Proteins/analysis , Pancreatic Neoplasms/chemistry , Pancreatic Neoplasms/pathology , Phenotype , Proto-Oncogene Proteins/analysis , Telomere Homeostasis , Tumor Burden , X-linked Nuclear ProteinABSTRACT
INTRODUCTION: Northwestern Ontario is a large rural area with a high concentration of remote First Nations communities. In Ontario, the highest hospital admission rates for pneumonia are reported from northern and rural regions. However, data are lacking on the epidemiology of community-acquired pneumonia in northwestern Ontario. We sought to characterize cases of community-acquired pneumonia requiring admission at the Sioux Lookout Meno Ya Win Health Centre, which serves a primarily First Nations population of 28,000. METHODS: We undertook a 3-year review of cases of community-acquired pneumonia requiring hospital admission at the centre. We used multivariable logistic regression to identify independent variables predictive of adverse outcomes. RESULTS: The annual incidence of hospital admissions related to community-acquired pneumonia was 3.42 per 1000 population. Of the 287 patients, 87% were First Nations and 52% were female. There was a high prevalence of diabetes, and chronic cardiovascular, renal and pulmonary diseases. Hospital admissions for community-acquired pneumonia were most prevalent among young children and older adults; both age groups had low coverage with recommended pneumococcal vaccines. Adverse outcomes included 10 deaths (3%) and 35 transfers to an intensive care facility (12%). Chronic renal disease and nonreceipt of azithromycin at initial presentation were identified as 2 independent predictors of an adverse outcome; there was a trend toward an increased risk of an adverse outcome in individuals with chronic obstructive pulmonary disease. CONCLUSION: Our findings emphasize the importance of preventing pneumonia in First Nations communities in northwestern Ontario. Research focusing on the distinct epidemiology of community-acquired pneumonia in this population is needed.
INTRODUCTION: Le Nord-Ouest de l'Ontario est une vaste région rurale où se trouve une forte concentration de communautés éloignées des Premières Nations. En Ontario, les taux les plus élevés d'hospitalisation en raison d'une pneumonie sont observés dans les régions du Nord et en milieu rural. On manque cependant de données sur l'épidémiologie de la pneumonie extrahospitalière dans le Nord-Ouest de l'Ontario. Nous avons cherché à caractériser les cas de pneumonie extrahospitalière nécessitant une admission au Centre de santé Sioux Lookout Meno Ya Win, qui dessert une population de 28 000 habitants principalement composée de membres des Premières Nations. MÉTHODES: Nous avons entrepris une revue répartie sur 3 ans des cas de pneumonie extrahospitalière ayant nécessité une admission à ce centre. Nous avons utilisé une méthode de régression logistique à variables multiples pour identifier des variables indépendantes permettant de prévoir la survenue d'événements défavorables. RÉSULTATS: L'incidence annuelle des hospitalisations reliées à la pneumonie extrahospitalière était de 3,42 pour 1000 habitants. Parmi les 287 patients, 87 % étaient des membres des Premières Nations et 52 % étaient de sexe féminin. On a enregistré une prévalence élevée de diabète, de maladie cardiovasculaire chronique, de maladie rénale et de maladie pulmonaire. La prévalence des hospitalisations en raison d'une pneumonie extrahospitalière était particulièrement élevée chez les jeunes enfants et les adultes âgés; dans ces deux groupes d'âge, le taux de couverture par les vaccins recommandés contre le pneumocoque était faible. Les événements défavorables ont été 10 décès (3 %) et 35 transferts vers l'unité de soins intensifs (12 %). Deux variables indépendantes relevées chez les patients au moment de l'hospitalisation ont été prédictives d'événements indésirables : la maladie rénale chronique et la non-réception d'azithromycine; on a observé une tendance à un risque accru d'événements indésirables chez les personnes atteintes de maladie pulmonaire obstructive chronique. CONCLUSION: Nos observations soulignent l'importance de la prévention de la pneumonie dans les communautés des Premières Nations du Nord-Ouest de l'Ontario. Il faudrait mener des études sur les particularités épidémiologiques de la pneumonie extrahospitalière dans cette population.
Subject(s)
Community-Acquired Infections/epidemiology , Community-Acquired Infections/therapy , Indians, North American/statistics & numerical data , Patient Admission/statistics & numerical data , Pneumonia, Bacterial/therapy , Female , Humans , Male , Ontario/epidemiology , Pneumonia, Bacterial/epidemiology , Population Surveillance , Residence CharacteristicsABSTRACT
BACKGROUND: Congenital pericardial defects occur from a defect in the formation of the pleuropericardial membrane during embryonic development. This defect may be asymptomatic but can be fatal if complicated by herniation of any portion of the heart. CASES: We report two cases in which herniation of a portion of the heart occurred through a partial left pericardial defect and resulted in fetal death. In case one, there were no fetal symptoms, and in case two, an irregular heartbeat was detected prompting a fetal echocardiogram that was negative for heart abnormalities. CONCLUSION: Although isolated congenital pericardial defects are rare, they can result in fetal death. Awareness may help to refine ultrasonography or other diagnostic modalities to evaluate possible congenital pericardial defects in utero.
Subject(s)
Heart Defects, Congenital/complications , Hernia/congenital , Pericardium/abnormalities , Adult , Female , Fetal Death , Hernia/etiology , Humans , PregnancyABSTRACT
The incidence of intrahepatic cholangiocarcinoma is increasing worldwide. The prognosis of intrahepatic cholangiocarcinoma is poor, and a better understanding of intrahepatic cholangiocarcinoma tumor biology is needed to more accurately predict clinical outcome and to suggest potential targets for more effective therapies. v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and BRAF are frequently mutated oncogenes that promote carcinogenesis in a variety of tumor types. In this study, we analyze a large set of intrahepatic cholangiocarcinoma tumors (n = 54) for mutations in these genes and compare the clinical outcomes of wild type versus KRAS and BRAF mutant cases. Of 54 cases, 7.4% were mutant for KRAS, 7.4% were mutant for BRAF, and these were mutually exclusive. These mutant cases were associated with a higher tumor stage at time of resection and a greater likelihood of lymph node involvement. These cases were also associated with a worse long-term overall survival. Therefore, testing for KRAS and BRAF mutations could be a valuable adjunct in improving both prognosis and outcome stratification among patients with intrahepatic cholangiocarcinoma.
Subject(s)
Cholangiocarcinoma/genetics , Liver Neoplasms/genetics , Mutation , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins/genetics , ras Proteins/genetics , Aged , Cholangiocarcinoma/mortality , Cholangiocarcinoma/pathology , Female , Humans , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Prognosis , Proto-Oncogene Proteins p21(ras) , Survival RateABSTRACT
PURPOSE: Dominant-negative growth hormone gene (GH1) mutations cause familial isolated growth hormone deficiency type II (IGHD II), which is characterized by GH deficiency, occasional multiple anterior pituitary hormone deficiencies, and anterior pituitary hypoplasia. We have previously shown that 17.5-/22-kDa GH1 transcript ratios correlate with the severity of the IGHD II phenotype. We hypothesized that different pharmaceutical agents could affect the GH1 transcript ratio by modulating alternative splicing. METHODS: We exposed peripheral blood mononuclear cells from IGHD II patients and unaffected family members to different pharmacologic agents and then determined the 17.5-/22-kDa transcript ratios by real-time PCR. RESULTS: Dexamethasone and digoxin significantly increased the 17.5-/22-kDa transcript ratio, while sodium butyrate and 5-iodotubericidin significantly decreased the ratio. CONCLUSION: Since we have previously shown that the ratio of the 17.5-/22-kDa GH1 transcripts correlates with severity of the IGHD II phenotype, our findings here suggest that selected previously unconsidered agents could possibly reduce the severity of IGHD II, while other agents could possibly exacerbate the disease phenotype.
Subject(s)
Growth Hormone/deficiency , Growth Hormone/genetics , Mutation , Pituitary Diseases/drug therapy , Pituitary Diseases/genetics , Cell Line , Dexamethasone/pharmacology , Digoxin/pharmacology , Family Health , Genes, Dominant , Humans , Leukocytes, Mononuclear/drug effects , Phenotype , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Sodium Oxybate/pharmacology , Tubercidin/analogs & derivatives , Tubercidin/pharmacologyABSTRACT
During vertebrate neural development, many dividing neuroepithelial precursors adopt features of radial glia, which are now known to also serve as neural precursors. In mammals, most radial glia do not persist past early postnatal stages, whereas zebrafish maintain large numbers of radial glia into adulthood. The mechanisms that maintain and specify radial glia for different fates are still poorly understood. We investigated formation of radial glia in the spinal cord of zebrafish and the role of Notch signaling in their maintenance and specification. We found that spinal cord precursors begin to express gfap+, a marker of radial glia, during neurogenesis and that gfap cells give rise to both neurons and oligodendrocytes. We also determined that Notch signaling is continuously required during embryogenesis to maintain radial glia, limit motor neuron formation and permit oligodendrocyte development, but that radial glia seem to be refractory to changes in Notch activity in postembryonic animals.